Treatment of Immunotherapy-Induced Pneumonitis
For grade 1-2 pneumonitis, initiate oral prednisone 1 mg/kg/day; for grade 3-4 pneumonitis, hospitalize immediately and start intravenous methylprednisolone 2-4 mg/kg/day, permanently discontinue the checkpoint inhibitor, and taper steroids slowly over 6+ weeks. 1, 2
Grade-Specific Treatment Algorithm
Grade 1 (Asymptomatic, Radiographic Changes Only)
- Hold the checkpoint inhibitor and monitor closely with clinical assessment every 2-3 days and repeat chest CT every 3 weeks 3, 4
- No corticosteroids are required at this stage 3, 4
- Continue surveillance with home pulse oximetry monitoring 3
- May consider reintroducing immunotherapy if imaging abnormalities resolve completely 3
Grade 2 (Symptomatic, Not Limiting ADLs)
- Permanently hold the checkpoint inhibitor 4
- Initiate oral prednisone 1 mg/kg/day (or IV methylprednisolone equivalent) 1, 4
- Rule out infection with bronchoscopy and bronchoalveolar lavage before starting immunosuppression when feasible 1
- If infection cannot be excluded, administer broad-spectrum antibiotics concurrently with steroids 1
- Reassess clinically every 2-3 days and radiologically to confirm improvement 1
- Taper steroids over 4-6 weeks after recovery 1
- Consider hospitalization for pulmonary and infectious disease consultation 4
Grade 3-4 (Severe, Limiting Self-Care or Life-Threatening)
- Hospitalize immediately and permanently discontinue checkpoint inhibitor 1, 4
- Initiate high-dose IV methylprednisolone 2-4 mg/kg/day 1, 2
- Consider ICU-level care for grade 4 pneumonitis 4
- If no improvement after 48 hours, add second-line immunosuppression: infliximab, mycophenolate mofetil, or cyclophosphamide 1
- Taper steroids very slowly over 6+ weeks to minimize relapse risk 1, 2
Critical Supportive Care Measures
Infection Prophylaxis
- Pneumocystis jirovecii pneumonia (PCP) prophylaxis for patients receiving ≥20 mg prednisone equivalent for ≥4 weeks 5, 4
- Proton pump inhibitor therapy for GI prophylaxis in all patients receiving steroids for grade 2-4 pneumonitis 5, 4
- T-spot testing to exclude tuberculosis before initiating anti-TNF therapy 4
Bone and Metabolic Protection
- Calcium and vitamin D supplementation with prolonged steroid use 5, 4
- Consider bone density testing and prophylactic bisphosphonates for long-term steroid therapy 5
- Monitor blood glucose regularly and treat hyperglycemia per standard guidelines 5
Infectious Workup (Grade 2+)
- Nasal swab, sputum culture, blood culture, urine culture 4
- COVID-19 testing per institutional guidelines 4
- Pulse oximetry and CT chest with contrast (if pulmonary embolus suspected) 4
Steroid-Refractory Pneumonitis
Approximately 10% of patients with ICI pneumonitis will be steroid-refractory or steroid-resistant, requiring second-line immunosuppression 6. When steroids fail after 48 hours:
Second-Line Options
- Cyclophosphamide appears most promising based on limited data, with 2/2 survivors at 5 months in one series 6
- Infliximab (single dose may suffice) 1, 6
- Mycophenolate mofetil 1, 5
- Intravenous immunoglobulin (IVIG) for severe cases unresponsive to steroids 7
- Pulse corticosteroid therapy (methylprednisolone 500 mg for 3 days) for steroid-refractory cases 8
Critical caveat: Mortality in steroid-refractory pneumonitis is high at 67%, emphasizing the importance of early recognition and aggressive management 6.
Chronic ICI Pneumonitis
Approximately 2% of patients with NSCLC or melanoma will develop chronic pneumonitis requiring ≥12 weeks of immunosuppression 9. These patients have distinct features:
- Recrudescence typically occurs when steroids tapered to ≤10 mg prednisone 9
- Median total steroid duration is 37 weeks (range: 16-43+ weeks) 9
- Characterized by persistent BALF lymphocytosis and organizing pneumonia pattern on biopsy 9
- Low-dose prednisone maintenance (10 mg daily) may be required long-term to prevent recurrence 10, 9
- Despite prolonged immunosuppression, most maintain disease control from ICIs 9
Rechallenge Considerations
- Grade 1: May rechallenge after complete resolution with close monitoring 2
- Grade 2: Rechallenge can be considered on an individual basis upon complete symptom resolution, only after steroids tapered to ≤10 mg prednisone daily 1, 2
- Grade 3-4: Checkpoint inhibitor should be permanently discontinued 1, 4
Common Pitfalls to Avoid
- Never delay steroid initiation in symptomatic patients while awaiting bronchoscopy results 4
- Avoid rapid steroid tapers: Grade 2 requires >1 month taper; grade 3-4 requires >2 months 4
- Do not use high-dose steroids (1 mg/kg/day) for endocrine immune-related adverse events 4
- Never continue long-term corticosteroid monotherapy without objective evidence of benefit 5
- Relapses during steroid tapering are common—maintain vigilance and be prepared to re-escalate 1
Risk Factors and Epidemiology
- Higher incidence with combination immunotherapy (10%) versus monotherapy (3%) 1, 11
- NSCLC patients have higher rates and more treatment-related deaths than melanoma patients 1
- Median time to onset: 2.5-2.8 months, occurring earlier with combination therapy 1, 11
- Pre-existing COPD, prior radiation therapy, and smoking history may increase risk 2